Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
TET2 mutation
i
Other names:
TET2, Tet Methylcytosine Dioxygenase 2, KIAA1546, Methylcytosine Dioxygenase TET2, Tet Oncogene Family Member 2, Probable Methylcytosine Dioxygenase TET2, MDS
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
54790
Related biomarkers:
Mutation
CNA
Others
‹
TET2 deletion + DNMT3A mutation (4)
KDM6B overexpression + TET2 deletion (1)
TET2 deletion + DNMT3A mutation (4)
KDM6B overexpression + TET2 deletion (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
TET2 mutation
Myelodysplastic Syndrome
TET2 mutation
Myelodysplastic Syndrome
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
ruxolitinib
Sensitive: A2 - Guideline
ruxolitinib
Sensitive
:
A2
TET2 mutation
Acute Myelogenous Leukemia
TET2 mutation
Acute Myelogenous Leukemia
cytarabine/daunorubicin liposomal formulation
Resistant: C2 – Inclusion Criteria
cytarabine / daunorubicin liposomal formulation
Resistant
:
C2
cytarabine/daunorubicin liposomal formulation
Resistant: C2 – Inclusion Criteria
cytarabine / daunorubicin liposomal formulation
Resistant
:
C2
TET2 mutation
Acute Myelogenous Leukemia
TET2 mutation
Acute Myelogenous Leukemia
azacitidine
Sensitive: C2 – Inclusion Criteria
azacitidine
Sensitive
:
C2
azacitidine
Sensitive: C2 – Inclusion Criteria
azacitidine
Sensitive
:
C2
TET2 mutation
Myelodysplastic Syndrome
TET2 mutation
Myelodysplastic Syndrome
azacitidine
Sensitive: C2 – Inclusion Criteria
azacitidine
Sensitive
:
C2
azacitidine
Sensitive: C2 – Inclusion Criteria
azacitidine
Sensitive
:
C2
TET2 mutation
Acute Myelogenous Leukemia
TET2 mutation
Acute Myelogenous Leukemia
HAG + azacitidine
Sensitive: C2 – Inclusion Criteria
HAG + azacitidine
Sensitive
:
C2
HAG + azacitidine
Sensitive: C2 – Inclusion Criteria
HAG + azacitidine
Sensitive
:
C2
TET2 mutation
Myelodysplastic Syndrome
TET2 mutation
Myelodysplastic Syndrome
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
TET2 mutation
Acute Myelogenous Leukemia
TET2 mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
TET2 mutation
Acute Myelogenous Leukemia
TET2 mutation
Acute Myelogenous Leukemia
cytarabine
Sensitive: C3 – Early Trials
cytarabine
Sensitive
:
C3
cytarabine
Sensitive: C3 – Early Trials
cytarabine
Sensitive
:
C3
TET2 mutation
Acute Myelogenous Leukemia
TET2 mutation
Acute Myelogenous Leukemia
quizartinib
Sensitive: C3 – Early Trials
quizartinib
Sensitive
:
C3
quizartinib
Sensitive: C3 – Early Trials
quizartinib
Sensitive
:
C3
TET2 mutation
T Cell Non-Hodgkin Lymphoma
TET2 mutation
T Cell Non-Hodgkin Lymphoma
lenalidomide
Resistant: C3 – Early Trials
lenalidomide
Resistant
:
C3
lenalidomide
Resistant: C3 – Early Trials
lenalidomide
Resistant
:
C3
TET2 mutation
Peripheral T-cell Lymphoma
TET2 mutation
Peripheral T-cell Lymphoma
CHOP
Sensitive: C3 – Early Trials
CHOP
Sensitive
:
C3
CHOP
Sensitive: C3 – Early Trials
CHOP
Sensitive
:
C3
TET2 mutation
Myelodysplastic Syndrome
TET2 mutation
Myelodysplastic Syndrome
sintilimab
Sensitive: C3 – Early Trials
sintilimab
Sensitive
:
C3
sintilimab
Sensitive: C3 – Early Trials
sintilimab
Sensitive
:
C3
TET2 mutation
Acute Myelogenous Leukemia
TET2 mutation
Acute Myelogenous Leukemia
venetoclax + decitabine/cedazuridine
Sensitive: C3 – Early Trials
venetoclax + decitabine / cedazuridine
Sensitive
:
C3
venetoclax + decitabine/cedazuridine
Sensitive: C3 – Early Trials
venetoclax + decitabine / cedazuridine
Sensitive
:
C3
TET2 mutation
Acute Myelogenous Leukemia
TET2 mutation
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Resistant: C3 – Early Trials
gemtuzumab ozogamicin
Resistant
:
C3
gemtuzumab ozogamicin
Resistant: C3 – Early Trials
gemtuzumab ozogamicin
Resistant
:
C3
TET2 mutation
Chronic Myelomonocytic Leukemia
TET2 mutation
Chronic Myelomonocytic Leukemia
azacitidine
Sensitive: C3 – Early Trials
azacitidine
Sensitive
:
C3
azacitidine
Sensitive: C3 – Early Trials
azacitidine
Sensitive
:
C3
TET2 mutation
Peripheral T-cell Lymphoma
TET2 mutation
Peripheral T-cell Lymphoma
CHOP + azacitidine oral
Sensitive: C3 – Early Trials
CHOP + azacitidine oral
Sensitive
:
C3
CHOP + azacitidine oral
Sensitive: C3 – Early Trials
CHOP + azacitidine oral
Sensitive
:
C3
TET2 mutation
Lymphoma
TET2 mutation
Lymphoma
azacitidine + romidepsin
Sensitive: C3 – Early Trials
azacitidine + romidepsin
Sensitive
:
C3
azacitidine + romidepsin
Sensitive: C3 – Early Trials
azacitidine + romidepsin
Sensitive
:
C3
TET2 mutation
Acute Myelogenous Leukemia
TET2 mutation
Acute Myelogenous Leukemia
talazoparib
Sensitive: D – Preclinical
talazoparib
Sensitive
:
D
talazoparib
Sensitive: D – Preclinical
talazoparib
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login